Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
- PMID: 20043028
- DOI: 10.1038/nrd3010
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Abstract
Small interfering RNAs (siRNAs) are widely used to study gene function owing to the ease with which they silence target genes, and there is considerable interest in their potential for therapeutic applications. In a remarkably short time since their discovery, siRNAs have entered human clinical trials in various disease areas. However, rapid acceptance of the use of siRNAs has been accompanied by recognition of several hurdles for the technology, including a lack of specificity. Off-target activity can complicate the interpretation of phenotypic effects in gene-silencing experiments and can potentially lead to unwanted toxicities. Here, we describe the types of off-target effects of siRNAs and methods to mitigate them, to help enable effective application of this exciting technology.
Similar articles
-
Applying small RNA molecules to the directed treatment of human diseases: realizing the potential.Expert Opin Ther Targets. 2008 Jan;12(1):115-27. doi: 10.1517/14728222.12.1.115. Expert Opin Ther Targets. 2008. PMID: 18076375 Review.
-
RNA-based drugs: from RNA interference to short interfering RNAs.Curr Pharm Biotechnol. 2004 Aug;5(4):361-8. doi: 10.2174/1389201043376797. Curr Pharm Biotechnol. 2004. PMID: 15320767 Review.
-
siRNA: a potential tool for future breast cancer therapy?Crit Rev Oncog. 2006 Jul;12(1-2):127-50. doi: 10.1615/critrevoncog.v12.i1-2.70. Crit Rev Oncog. 2006. PMID: 17078209 Review.
-
The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.Methods Mol Biol. 2009;487:189-203. doi: 10.1007/978-1-60327-547-7_9. Methods Mol Biol. 2009. PMID: 19301648 Review.
-
Oncogene suppression by small interfering RNAs.Curr Pharm Biotechnol. 2004 Aug;5(4):349-54. doi: 10.2174/1389201043376733. Curr Pharm Biotechnol. 2004. PMID: 15320765 Review.
Cited by
-
Measurement of Cancer Cell Growth Heterogeneity through Lentiviral Barcoding Identifies Clonal Dominance as a Characteristic of In Vivo Tumor Engraftment.PLoS One. 2013 Jun 26;8(6):e67316. doi: 10.1371/journal.pone.0067316. Print 2013. PLoS One. 2013. PMID: 23840661 Free PMC article.
-
Genes regulating membrane-associated E-cadherin and proliferation in adenomatous polyposis coli mutant colon cancer cells: High content siRNA screen.PLoS One. 2020 Oct 15;15(10):e0240746. doi: 10.1371/journal.pone.0240746. eCollection 2020. PLoS One. 2020. PMID: 33057364 Free PMC article.
-
Epigenetic mechanisms in Alzheimer's disease.Degener Neurol Neuromuscul Dis. 2014 May 24;4:85-102. doi: 10.2147/DNND.S37341. eCollection 2014. Degener Neurol Neuromuscul Dis. 2014. PMID: 32669903 Free PMC article.
-
SHAPE-directed discovery of potent shRNA inhibitors of HIV-1.Mol Ther. 2012 Apr;20(4):820-8. doi: 10.1038/mt.2011.299. Epub 2012 Feb 7. Mol Ther. 2012. PMID: 22314289 Free PMC article.
-
Spermidine attenuates chondrocyte inflammation and cellular pyroptosis through the AhR/NF-κB axis and the NLRP3/caspase-1/GSDMD pathway.Front Immunol. 2024 Oct 2;15:1462777. doi: 10.3389/fimmu.2024.1462777. eCollection 2024. Front Immunol. 2024. PMID: 39416781 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
